Quercetin is one of natural flavonoids. It has ability to hinder neovascularization in cancers by reducing activities of the vascular endothelial growth factor-A (VEGF-A). Regarding this particular activity, quercetin thus has a potential for managing the vasoproliferative retinopathies. Unfortunately, its hydrophobicity resulted in poor ocular bioavailability. A suitable intravitreal formulation should be developed to overcome this problem. This study was conducted to optimize formulations of thermoresponsive quercetin nanoemulgels (T-QNE-Gs) for intravitreal injection and to examine their in vitro for their inhibitory activity on VEGF-A inducing neovascularization from the retinal pigment endothelial cells. T-QNE-Gs were prepared by incorporation of gels consisting of various ratios of Pluronic F127 (F127) to Pluronic F68 (F68), with a fixed concentration of hydroxypropyl methylcellulose, into a quercetin nanoemulsion concentrate. The optimum formulation of T-QNE-Gs was 2F127-1F68 containing F127 and F68 at a 2:1 ratio. After sterilization, S-2F127-1F68 was obtained. The S-2F127-1F68 could flow properly at a room temperature (27±1°C) and became gel at a temperature of the posterior eye segment (35±1°C). It effectively inhibited migration and tube formation of the human umbilical vein endothelial cells and suppressed the VEGF-A gene expression and VEGF-A protein levels in the arising retinal pigment epithelial cells under a hypoxic condition. Therefore, S-2F127-1F68 had a potential for treatment of the the vassoproliferative retinopathies and can be used for further investigation in animal models.